Hung T, Bang L, Van Duyet L
J Clin Lab Anal. 2025; 39(5):e25157.
PMID: 39907180
PMC: 11904817.
DOI: 10.1002/jcla.25157.
Dagba Gbessin E, Tchiakpe E, Keke R, Vidal N, Gomgnimbou M, Sina H
PLoS One. 2025; 20(1):e0317882.
PMID: 39879199
PMC: 11778783.
DOI: 10.1371/journal.pone.0317882.
Byun H, Papathanasopoulos M, Steegen K, Basson A
Viruses. 2025; 16(12.
PMID: 39772195
PMC: 11680407.
DOI: 10.3390/v16121888.
Yan J, Nan H, Fang X, Long X, Jiang Y, Liu J
Front Pharmacol. 2024; 15:1477878.
PMID: 39717550
PMC: 11663674.
DOI: 10.3389/fphar.2024.1477878.
Cho Y, Lee J, Kim J, Sung H
J Ginseng Res. 2024; 48(6):603-608.
PMID: 39583165
PMC: 11583472.
DOI: 10.1016/j.jgr.2024.09.003.
COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.
Bou-Antoun S, Rokadiya S, Ashiru-Oredope D, Demirjian A, Sherwood E, Ellaby N
J Antimicrob Chemother. 2023; 78(Suppl 2):ii37-ii42.
PMID: 37995354
PMC: 10666993.
DOI: 10.1093/jac/dkad314.
Modeling Drug Resistance Emergence and Transmission in HIV-1 in the UK.
Zhukova A, Dunn D, Gascuel O
Viruses. 2023; 15(6).
PMID: 37376544
PMC: 10304371.
DOI: 10.3390/v15061244.
Development and validation of a scoring system for the prediction of HIV drug resistance in Hubei province, China.
Yan J, Zhang W, Luo H, Wang X, Ruan L
Front Cell Infect Microbiol. 2023; 13:1147477.
PMID: 37234779
PMC: 10208424.
DOI: 10.3389/fcimb.2023.1147477.
2022 update of the drug resistance mutations in HIV-1.
Wensing A, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard H, Paredes R
Top Antivir Med. 2022; 30(4):559-574.
PMID: 36375130
PMC: 9681141.
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Choudhary M, Chew K, Deo R, Flynn J, Regan J, Crain C
Nat Microbiol. 2022; 7(11):1906-1917.
PMID: 36289399
PMC: 9675946.
DOI: 10.1038/s41564-022-01254-1.
Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2.
Patel D, Ono S, Bassit L, Verma K, Amblard F, Schinazi R
Molecules. 2022; 27(17).
PMID: 36080181
PMC: 9457688.
DOI: 10.3390/molecules27175413.
Molecular adaptations during viral epidemics.
Rochman N, Wolf Y, Koonin E
EMBO Rep. 2022; 23(8):e55393.
PMID: 35848484
PMC: 9346483.
DOI: 10.15252/embr.202255393.
Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies.
Singh A, Das K
Viruses. 2022; 14(5).
PMID: 35632767
PMC: 9148108.
DOI: 10.3390/v14051027.
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Tachbele E, Kyobe S, Katabazi F, Kigozi E, Mwesigwa S, Joloba M
Infect Drug Resist. 2021; 14:4833-4847.
PMID: 34819737
PMC: 8607991.
DOI: 10.2147/IDR.S337485.
Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
Cilento M, Reeve A, Michailidis E, Ilina T, Nagy E, Mitsuya H
Antimicrob Agents Chemother. 2021; 65(12):e0116721.
PMID: 34516245
PMC: 8597736.
DOI: 10.1128/AAC.01167-21.
Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C.
Posada-Cespedes S, van Zyl G, Montazeri H, Kuipers J, Rhee S, Kouyos R
PLoS Comput Biol. 2021; 17(9):e1008363.
PMID: 34491984
PMC: 8448360.
DOI: 10.1371/journal.pcbi.1008363.
Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity.
Feder A, Harper K, Brumme C, Pennings P
Elife. 2021; 10.
PMID: 34473060
PMC: 8412921.
DOI: 10.7554/eLife.69032.
A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants.
Colson P, Devaux C, Lagier J, Gautret P, Raoult D
J Clin Med. 2021; 10(15).
PMID: 34362060
PMC: 8348317.
DOI: 10.3390/jcm10153276.
Avoiding Drug Resistance in HIV Reverse Transcriptase.
Cilento M, Kirby K, Sarafianos S
Chem Rev. 2021; 121(6):3271-3296.
PMID: 33507067
PMC: 8149104.
DOI: 10.1021/acs.chemrev.0c00967.
AP-1 and NF-κB synergize to transcriptionally activate latent HIV upon T-cell receptor activation.
Hokello J, Sharma A, Tyagi M
FEBS Lett. 2021; 595(5):577-594.
PMID: 33421101
PMC: 8073299.
DOI: 10.1002/1873-3468.14033.